Health
New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare
PALO ALTO, Calif., March 13, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new national survey conducted on its behalf by The Harris Poll with findings demonstrating that more than 9 out of 10 Americans ages 45 and over believe in ensuring broader coverage for blood-based colorectal cancer (CRC) screening, including new innovations like Shield™ by Guardant, a methylation partitioning cell-free DNA (mp-cfDNA) test and the first an
About this update from Guardant Health, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1806,"height":619,"url":"https://media.zenfs.com/en/business-wire.com/e9b8842953fb3b094554d7e37e300a45"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YqD2kY9cmjjyZCb7lq12zw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyOTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e9b8842953fb3b094554d7e37e300a45","width":960,"height":329},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Ck19tShwWsunTw50Po4JTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MjI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/e9b8842953fb3b094554d7e37e300a45","width":1200,"height":411}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Survey highlights barriers to colorectal cancer screening for adults 45 and over","length":80,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Overwhelming majority (92%) of Americans ages 45 and over believe blood-based screening should be covered with no co-pay","length":120,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Shield™ by Guardant is proven to increase screening rates with a 93% adherence rate by offering a quick, easy option to screen with just a blood draw","length":149,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":349,"olType":false},{"type":"text","content":"PALO ALTO, Calif., March 13, 2026--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new national survey conducted on its behalf by The Harris Poll with findings demonstrating that more than 9 out of 10 Americans ages 45 and over believe in ensuring broader coverage for blood-based colorectal cancer (CRC) screening, including new innovations like Shield™ by Guardant, a methylation partitioning cell-free DNA (mp-cfDNA) test and the first and only FDA-approved blood test for primary colorectal cancer screening.","length":588,"tagName":"p"},{"type":"text","content":"The survey showed an overwhelming majority of Americans of screening-eligible age (92%) believe that blood-based colorectal cancer screening should be covered with no co-pay similar to Medicare Part B and VA Community Care coverage. National CRC screening guidelines from the United States Preventive Service...